Marker Therapeutics Inc (MRKR)
followers
·
Follow
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Peter L. Hoang
Employees:
60
4551 KENNEDY COMMERCE DR., HOUSTON, TX, 77032
(713) 400-6400
-
Formally known as:
- TapImmune Inc
- TAPIMMUNE INC NEW COM STK (NV)
- TAPIMMUNE INC NEW COMMON STOCK
- TAPIMMUNE INC. NEW COMMON STOCK
Date | Ratio |
---|---|
2001-06-08 | 1:5 |
2007-06-28 | 10:25 |
2009-07-27 | 1:1 |
2014-02-25 | 1:100 |
2016-09-16 | 1:12 |
2023-01-27 | 1:10 |
Marker Therapeutics, Inc. engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors. It is also developing TPIV100/110 and TPIV200, which is in Phase 2 clinical trials for breast and ovarian cancers.
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|